Remdesivir

Indications & Dose:

Treatment of coronavirus disease 2019 (COVID-19) in adults and adolescents (aged twelve years and older with body weight at least 40

kilograms (88 lb)) with pneumonia requiring supplemental oxygen and requiring hospitalization. injection, lyophilized powder for reconstitution

100mg/vial injection, concentrated solution 100mg/20mL (5mg/mL)

Coronavirus Disease 2019 (COVID-19)

Indicated for adults and pediatric patients aged =12 years who weigh =40 kg for treatment of COVID-19 requiring hospitalization\Day 1 loading

dose: 200 mg IV infused over 30-120 min, THEN Day 2 and thereafter: 100 mg IV qDay

Treatment duration

Not requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO): 5 days; if clinical improvement not

demonstrated, treatment may be extended up to 10 days total Requires invasive mechanical ventilation and/or ECMO: 10 days

Contraindications:

Side Effects:

The most common adverse effects in studies of remdesivir for COVID-19 include respiratory failure and organ impairment, including low albumin,

low potassium, low count of red blood cells, low count of platelets that help with clotting, and yellow discoloration of the skin. Other reported side

effects include gastrointestinal distress, elevated transaminase levels in the blood (liver enzymes), and infusion site reactions.\Other possible side

effects of remdesivir include: Infusion-related reactions. Infusion-related reactions have been seen during a remdesivir infusion or around the

time remdesivir was given.  Signs and symptoms of infusion-related reactions may include: low blood pressure, nausea, vomiting, sweating, and

shivering.  Increases in levels of liver enzymes, seen in abnormal liver blood tests.[  Increases in levels of liver enzymes have been seen in

people who have received remdesivir, which may be a sign of inflammation or damage to cells in the liver. 

Cautions:

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Renal impairment

Pharmacokinetics have not been evaluated in patients with renal impairment eGFR =30 mL/min: No dose adjustment eGFR<30 mL/min: Not

recommended; sulfobutylether-beta-cyclodextrin sodium salt (SBECD) excipient in the concentrated solution is renally cleared and accumulates in

patients with decreased renal function

Hepatic impairment

Not evaluated; unknown if dosage adjustment required Dosing Considerations

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: